ES2145425T3 - Comprimidos de valaciclovir que contienen dioxido de silicio coloidal. - Google Patents

Comprimidos de valaciclovir que contienen dioxido de silicio coloidal.

Info

Publication number
ES2145425T3
ES2145425T3 ES96900626T ES96900626T ES2145425T3 ES 2145425 T3 ES2145425 T3 ES 2145425T3 ES 96900626 T ES96900626 T ES 96900626T ES 96900626 T ES96900626 T ES 96900626T ES 2145425 T3 ES2145425 T3 ES 2145425T3
Authority
ES
Spain
Prior art keywords
silicon dioxide
tablets containing
valaciclovir
coloidal
valaciclovir tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96900626T
Other languages
English (en)
Spanish (es)
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145425(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2145425T3 publication Critical patent/ES2145425T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES96900626T 1995-01-20 1996-01-19 Comprimidos de valaciclovir que contienen dioxido de silicio coloidal. Expired - Lifetime ES2145425T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet

Publications (1)

Publication Number Publication Date
ES2145425T3 true ES2145425T3 (es) 2000-07-01

Family

ID=10768317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96900626T Expired - Lifetime ES2145425T3 (es) 1995-01-20 1996-01-19 Comprimidos de valaciclovir que contienen dioxido de silicio coloidal.

Country Status (38)

Country Link
US (1) US5879706A (enExample)
EP (1) EP0806943B1 (enExample)
JP (1) JP3350055B2 (enExample)
KR (1) KR100412298B1 (enExample)
CN (2) CN1313081C (enExample)
AP (1) AP666A (enExample)
AT (1) ATE190483T1 (enExample)
AU (1) AU710823B2 (enExample)
BG (1) BG63187B1 (enExample)
BR (1) BR9606769A (enExample)
CA (1) CA2210891C (enExample)
CY (1) CY2182B1 (enExample)
CZ (1) CZ296514B6 (enExample)
DE (1) DE69607146T2 (enExample)
DK (1) DK0806943T3 (enExample)
EA (1) EA000276B1 (enExample)
EE (1) EE03336B1 (enExample)
ES (1) ES2145425T3 (enExample)
FI (1) FI119722B (enExample)
GB (1) GB9501127D0 (enExample)
GE (1) GEP20022752B (enExample)
GR (1) GR3033677T3 (enExample)
HU (1) HU226131B1 (enExample)
IL (1) IL116830A (enExample)
IN (1) IN181318B (enExample)
MY (1) MY126346A (enExample)
NO (1) NO311488B1 (enExample)
NZ (1) NZ298846A (enExample)
OA (1) OA10500A (enExample)
PL (1) PL185307B1 (enExample)
PT (1) PT806943E (enExample)
RO (1) RO118175B1 (enExample)
SK (1) SK282030B6 (enExample)
TR (1) TR199700657T1 (enExample)
UA (1) UA68325C2 (enExample)
UY (2) UY25774A1 (enExample)
WO (1) WO1996022082A1 (enExample)
ZA (1) ZA96448B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
PT874631E (pt) * 1996-01-19 2004-04-30 Glaxo Group Ltd Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
ATE254907T1 (de) * 1998-12-18 2003-12-15 Abbott Lab Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EE200300537A (et) * 2001-05-01 2004-04-15 Pfizer Products Inc. Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
JP2005508993A (ja) * 2001-11-14 2005-04-07 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビルの合成及び精製
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
EP3395340B8 (en) 2003-09-12 2019-12-11 Amgen Inc. Rapid dissolution formulation of cinacalcet hcl
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ES2246034T3 (es) * 2003-12-09 2006-02-01 Helm Ag Formulacion farmaceutica de valaciclovir.
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
CN101484140B (zh) * 2006-05-10 2012-10-03 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
KR20090018843A (ko) * 2006-05-31 2009-02-23 버텍스 파마슈티칼스 인코포레이티드 인터류킨-1 베타 전환효소 억제제의 경구용 조절 방출 제제
SI2040684T1 (sl) * 2006-07-11 2013-06-28 Lek Pharmaceuticals D.D. Večenotne tablete
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
PL2407166T3 (pl) * 2009-03-13 2014-01-31 Toyama Chemical Co Ltd Tabletka i granulowany proszek zawierające 6-fluoro-3-hydroksy-2-pirazynokarboksamid
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
US20230201234A1 (en) * 2020-06-01 2023-06-29 Shilpa Medicare Ltd Fast dispersible pharmaceutical composition comprising capecitabine
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
CA3266275A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab PHARMACEUTICAL FORMULATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE68903605T2 (de) * 1988-05-04 1993-04-01 Smith Kline French Lab Kautablette.
BE1004461A5 (fr) * 1991-01-30 1992-11-24 Wellcome Found Comprimes dispersables dans l'eau.
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
US5879706A (en) 1999-03-09
EA000276B1 (ru) 1999-02-25
BG63187B1 (bg) 2001-06-29
OA10500A (en) 2002-04-10
ATE190483T1 (de) 2000-04-15
HUP9801872A2 (hu) 1999-10-28
CN1494898A (zh) 2004-05-12
FI973062A0 (fi) 1997-07-18
PT806943E (pt) 2000-08-31
SK282030B6 (sk) 2001-10-08
NZ298846A (en) 1998-06-26
MY126346A (en) 2006-09-29
HU226131B1 (en) 2008-05-28
BR9606769A (pt) 1997-12-30
EE03336B1 (et) 2001-02-15
NO973327L (no) 1997-09-16
CN1179100A (zh) 1998-04-15
PL185307B1 (pl) 2003-04-30
GEP20022752B (en) 2002-08-26
NO311488B1 (no) 2001-12-03
RO118175B1 (ro) 2003-03-28
CA2210891C (en) 2009-05-19
AU710823B2 (en) 1999-09-30
UA68325C2 (en) 2004-08-16
NO973327D0 (no) 1997-07-18
EP0806943B1 (en) 2000-03-15
UY25774A1 (es) 2000-10-31
GR3033677T3 (en) 2000-10-31
EP0806943A1 (en) 1997-11-19
EA199700123A1 (ru) 1997-12-30
AU4453496A (en) 1996-08-07
PL321361A1 (en) 1997-12-08
CZ296514B6 (cs) 2006-03-15
HK1002851A1 (en) 1998-09-25
GB9501127D0 (en) 1995-03-08
IN181318B (enExample) 1998-05-09
CY2182B1 (en) 2002-08-23
SK96497A3 (en) 1998-01-14
DE69607146D1 (de) 2000-04-20
FI119722B (fi) 2009-02-27
DE69607146T2 (de) 2000-09-21
IL116830A0 (en) 1996-05-14
FI973062L (fi) 1997-09-18
CZ229297A3 (cs) 1998-02-18
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
ZA96448B (en) 1996-08-07
TR199700657T1 (xx) 1998-02-21
CN1313081C (zh) 2007-05-02
UY25778A1 (es) 2000-08-21
KR100412298B1 (ko) 2004-04-21
KR19980701524A (ko) 1998-05-15
JP3350055B2 (ja) 2002-11-25
HUP9801872A3 (en) 2001-02-28
BG101831A (en) 1998-04-30
JPH10512564A (ja) 1998-12-02
IL116830A (en) 2000-02-29
MX9705459A (es) 1997-10-31
AP666A (en) 1998-08-24
AP9701057A0 (en) 1997-10-31
WO1996022082A1 (en) 1996-07-25
DK0806943T3 (da) 2000-07-24

Similar Documents

Publication Publication Date Title
ES2145425T3 (es) Comprimidos de valaciclovir que contienen dioxido de silicio coloidal.
BR9807742A (pt) EpotilÈneos que são modificados na cadeia lateral
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
TR200200644T2 (tr) Dallandırılmış polikarbonat konteynerleri.
CO5540327A2 (es) Composicion desecante
DK0734414T3 (da) Stabiliseret vinylchloridsammensætning
FR2678637B1 (fr) Nouvelles souches de levure pour la production de xylitol.
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
TR200201459T2 (tr) Okzkarbazepin içeren süspansiyon
EP0914653A4 (en) TWO-SIDED DVD-CD HYBRID DISC
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
GR3036142T3 (en) Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
DE50005444D1 (de) Selektive inhibitoren des urokinase-plasminogen aktivators
PL352104A1 (en) Oral composition containing perlite
MY100792A (en) Vitamin composition with enhances bioavailability
DE69316200D1 (de) Feuchtigkeitsspender
NO971097L (no) Fyllmiddel
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
NO943336L (no) Chinolinforbindelser
ES2184025T3 (es) Estante.
TR199800261U (xx) Oturma takımı mekanizması.
HN1997000108A (es) Derivado 6,6,6.6.7- biciclicas sustituido que contiene pirido o pirimido
PL348762A1 (en) Use of zinc alloys
UA16247A1 (uk) N-(3-ХЛОРО-1,4-HАФТОХІHОHІЛ-2)-2-Д, alРha-АСПАРАГІHОВУ КИСЛОТА, ЩО ПРОЯВЛЯЄ КАРДІОСТИМУЛЮЮЧІ ВЛАСТИВОСТІ
AR046718A1 (es) Compuestos de benzazepina y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 806943

Country of ref document: ES